Abstract
Myostatin purification -Human recombinant myostatin protein (hMstn) was cloned, were washed twice with cold PBS, resuspended in 1 mL of cold PBS and examined by flow 126 cytometry (FACSCalibur, Becton-Dickinson) using ModFit software (Becton-Dickinson).
127
Transient co-transfection -Transfections were performed on C2C12 myoblasts to test the 128 effect of hMstn treatment on Smad3 and Notch-1 intracellular domain (ICD) interaction.
129
C2C12 myoblasts were seeded on 10 cm 2 plates at a density of 10,000 synthesized using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) according to the 8 and mean myotube number (± S.E.M) from 3 coverslips per treatment was calculated.
170
Individual myotube area was assessed for all myotubes present in 10 random images taken were compared using one-way ANOVA, with a p value of <0.05 considered significant. hMstn-treated hMb5 cells (Table 1) . Concomitant with the increase in cells in the G 1 phase, from 3.9 to 5.9 % in hMb5 cells (Table 1) (supplemental Fig. 3 ) at 12 h after treatment with hMstn; at 24 h after hMstn treatment, Hes1,
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Hes5 and Hey1 expression was increased in hMb5 cells (Fig. 4A ), while only Hes5 was 276 upregulated in hMb15 cells (supplemental Fig. 3 ). consistent with the increased activation of Smad3 by myostatin (Fig. 2E) .
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The present study was conducted in an effort to improve the sparse knowledge base on 
